2023 World Conference on Lung Cancer (Posters)-P1.02. Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC

P1.02. Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC - PDF(Abstract)

Pdf Summary

This study focuses on the therapeutic strategy for KRAS-mutant non-small cell lung cancer (NSCLC). KRAS mutation is a common alteration in NSCLC, but an effective treatment for most KRAS mutation subtypes is still unknown. The researchers used various KRAS-mutant NSCLC cell lines to study the effects of co-inhibition of MEK and receptor tyrosine kinases (RTKs) pathways. They found that inhibiting IGFBP2, a protein involved in cell growth, enhanced the efficacy of the MEK inhibitor in treating KRAS-mutated NSCLC. They also discovered that blocking the MEK-trametinib-induced IGFBP2/c-MYC pathway with the RTKs inhibitor anlotinib reversed drug resistance in KRAS-mutated NSCLC. Furthermore, co-inhibition of the MEK and RTKs pathways showed synergistic effects in suppressing KRAS-mutant NSCLC. <br /><br />These findings provide insights into the molecular mechanisms of the MEK inhibitor trametinib and the RTKs inhibitor anlotinib in treating KRAS-mutant NSCLC. The study demonstrates the potential of combining anlotinib and trametinib as a novel treatment strategy for KRAS-mutant NSCLC. The research was conducted using in vitro and in vivo models, providing preclinical evidence for this combination therapy. <br /><br />Keywords for this study include KRAS-mutant NSCLC, targeted therapy, and molecular mechanism. The research falls into the tumor biology and preclinical biology track at WCLC 2023. The abstract is categorized as a regular abstract.

Asset Subtitle

Baohui Han

Meta Tag

Speaker Baohui Han

Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets

Keywords

KRAS-mutant NSCLC

therapeutic strategy

MEK inhibitor

RTKs pathways

IGFBP2

cell growth

trametinib

drug resistance

combination therapy

molecular mechanisms